Damora Therapeutics (DMRA) Assets Average (2020 - 2026)

Damora Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $398.0 million for Q1 2026.

• Quarterly Assets Average rose 2349.36% year-over-year to $398.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $398.0 million (up 2349.36% YoY) and the FY2025 annual result came in at $138.8 million, up 401.56% from the prior year.
• Assets Average was $398.0 million for Q1 2026 at Damora Therapeutics, up from $135.6 million in the prior quarter.
• Across five years, Assets Average topped out at $398.0 million in Q1 2026 and bottomed at $12.2 million in Q3 2025.
• A 5-year average of $76.4 million and a median of $54.4 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average tumbled 54.11% — and 2026, when it jumped 2349.36%.
• Damora Therapeutics' Assets Average stood at $77.6 million in 2022, then tumbled by 43.13% to $44.1 million in 2023, then slumped by 54.11% to $20.3 million in 2024, then jumped by 569.65% to $135.6 million in 2025, then jumped by 193.43% to $398.0 million in 2026.
• Business Quant data shows DMRA's Assets Average at $398.0 million in Q1 2026, $135.6 million in Q4 2025, and $12.2 million in Q3 2025.